National Bank of Canada FI Boosts Stake in Masimo Co. (NASDAQ:MASI)

National Bank of Canada FI boosted its stake in Masimo Co. (NASDAQ:MASI - Free Report) by 195.6% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 132,500 shares of the medical equipment provider's stock after buying an additional 87,675 shares during the quarter. National Bank of Canada FI owned approximately 0.25% of Masimo worth $17,666,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of MASI. NBC Securities Inc. lifted its position in shares of Masimo by 47.1% during the third quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider's stock valued at $30,000 after purchasing an additional 73 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of Masimo by 75.0% in the 2nd quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider's stock worth $33,000 after buying an additional 111 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Masimo by 133.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider's stock valued at $44,000 after acquiring an additional 200 shares in the last quarter. HHM Wealth Advisors LLC lifted its holdings in Masimo by 25.0% during the second quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider's stock worth $79,000 after acquiring an additional 125 shares during the period. Finally, Fifth Third Bancorp boosted its position in Masimo by 16.4% in the second quarter. Fifth Third Bancorp now owns 695 shares of the medical equipment provider's stock worth $88,000 after purchasing an additional 98 shares during the last quarter. 85.96% of the stock is currently owned by institutional investors.

Masimo Stock Performance

Masimo stock traded up $5.13 during mid-day trading on Tuesday, reaching $174.65. The company's stock had a trading volume of 798,956 shares, compared to its average volume of 667,204. The firm's fifty day moving average price is $154.88 and its two-hundred day moving average price is $132.21. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. Masimo Co. has a 12-month low of $101.35 and a 12-month high of $178.27. The company has a market capitalization of $9.35 billion, a P/E ratio of 120.45 and a beta of 1.01.

Masimo (NASDAQ:MASI - Get Free Report) last announced its quarterly earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.14. The company had revenue of $504.60 million during the quarter, compared to analysts' expectations of $502.87 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The firm's quarterly revenue was up 5.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.63 earnings per share. Sell-side analysts predict that Masimo Co. will post 4.03 EPS for the current fiscal year.

Analysts Set New Price Targets

MASI has been the topic of a number of recent analyst reports. Raymond James upgraded Masimo from a "market perform" rating to an "outperform" rating and set a $170.00 target price on the stock in a research note on Wednesday, November 6th. Wells Fargo & Company increased their target price on shares of Masimo from $160.00 to $171.00 and gave the company an "overweight" rating in a research report on Wednesday, November 6th. Needham & Company LLC reaffirmed a "hold" rating on shares of Masimo in a report on Wednesday, November 6th. Piper Sandler upped their price objective on Masimo from $165.00 to $180.00 and gave the company an "overweight" rating in a research note on Wednesday, November 6th. Finally, BTIG Research raised their target price on Masimo from $166.00 to $170.00 and gave the stock a "buy" rating in a research report on Monday, October 14th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $167.00.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.